Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ruxolitinib + NIS793
- Development stage
- Discontinued
- Lead developer
- Novartis
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral (ruxolitinib), Intravenous (NIS793)
01
Overview
**ruxolitinib + NIS793** is an investigational combination therapy comprised of ruxolitinib, a small molecule Janus kinase 1 and Janus kinase 2 inhibitor, and NIS793, a fully human IgG2 monoclonal antibody that binds to and inhibits transforming growth factor-beta 1 and 2 (TGF-β1, TGF-β2), with low affinity for TGF-β3. Ruxolitinib is an approved treatment for myelofibrosis, where it reduces disease symptoms and spleen size by inhibiting dysregulated JAK-STAT signaling. NIS793 modulates the tumor microenvironment by blocking TGF-β signaling, implicated in fibrosis, immune suppression, and the propagation of myeloid cancers. The combination is being developed for patients with myelofibrosis who have a suboptimal response to ruxolitinib alone. This approach aims to improve efficacy by targeting both cellular signaling (JAK-STAT) and fibrotic/immune pathways[1][3][4][7][9].
- Brand names
- None known for the combination
- Other names
- None known for the combination
02
Targets
JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)TGFB1 (Transforming growth factor Beta-1 proprotein)TGFB2 (Transforming growth factor beta 2)
Beyond the preview
Go deeper on ruxolitinib + NIS793.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ruxolitinib + NIS793.